About: Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 April 1998

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у квітні 1998 (uk) im April 1998 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'abril de 1998 (ast) scientific article published on 01 April 1998 (en)
publication date	wds:Q74428457-6F081D83-A720-4511-B081-693375028F74
publication date	1998-04-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q74428457-1E093EB1-41A0-4A33-8000-6239AB8D51B9
language of work or name	English
cites work	wds:Q74428457-1B330AEA-D1C8-4B98-A631-86F7B88E6D75 wds:Q74428457-22457ECD-7F1E-49E6-A839-51ECC77CA7D4 wds:Q74428457-236A5C5C-5F75-4DE8-971C-78F4C153BE63 wds:Q74428457-281742E5-441D-497D-B3A4-CE8E736380E9 wds:Q74428457-2881B943-213B-41BE-8E12-9EDD09C16A3C wds:Q74428457-3FBEA257-4B57-44B6-980C-968A38E3387D wds:Q74428457-469CD53D-FDD8-4B28-88DE-1CBF8103B3C8 wds:Q74428457-4EC84086-851C-4FE2-AFCC-662F7848091C wds:Q74428457-5259E277-3712-426C-9218-BBD94476F880 wds:Q74428457-63168562-5538-47B9-BE50-DCC4C9E5C4DD wds:Q74428457-64295ADA-988E-4374-A97F-05286888AAFE wds:Q74428457-684E23ED-589C-46A7-9965-3B11AD607F89 wds:Q74428457-6CE553ED-0909-4730-9DD9-00F1A8883ADB wds:Q74428457-6E87B69E-4940-41F4-92F2-5210C4FE7A0F wds:Q74428457-7F5E146F-5740-4F84-85B5-370630F6D09C wds:Q74428457-87F570FD-E2F5-4762-B6AE-E5A2E3B6B4B2 wds:Q74428457-8AF14134-9ADB-46B4-A90B-692D21FAC31A wds:Q74428457-8B408585-B256-4DDB-B268-B95E62E91714 wds:Q74428457-9825C145-E6FE-4929-B60C-B3A7290365DB wds:Q74428457-9D324013-6AC5-48A2-8AB1-F0644558AA1A wds:Q74428457-9EA4F71B-13E9-4A01-AFC7-960EAFFD4BFA wds:Q74428457-A15EEEA2-15BF-4E68-988F-625C0D7936AE wds:Q74428457-A2F3C170-3566-4790-8A42-0DDA6648C70F wds:Q74428457-AC157FFB-B314-475C-9529-82C1AD763245 wds:Q74428457-BC712C75-58DD-4BD2-9EF7-474A02B2FE7D wds:Q74428457-C4230833-02A3-4170-9BD7-91F16B1677C0 wds:Q74428457-CB1B6C46-8F4D-41C1-BB75-E40FA529FE77 wds:Q74428457-CF4FA0D9-8A79-498B-9056-F590955D8157 wds:Q74428457-DA644234-4C03-40E5-B03C-2FE6B431EC5E wds:Q74428457-FC8532E5-3960-4B33-8653-B5A56B26E97B
cites work	Clinical outcomes after transfusion-associated hepatitis C. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus Prediction of response to interferon treatment of chronic hepatitis C. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Non-A, non-B post-transfusion hepatitis. Looking back in the second decade Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. The long-term pathological evolution of chronic hepatitis C. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Interferon for non-A, non-B chronic hepatitis Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone Distribution of interferon-alpha 2 genes in humans. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study Factors predictive of the response to interferon in patients with chronic hepatitis C Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? Nomenclature of the human interferon proteins The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review
author name string	wds:Q74428457-642B6D86-56CB-4569-BF79-59D8BB4800D9 wds:Q74428457-660AB405-DF1B-4C38-9499-D30A9EEC4016 wds:Q74428457-9E7BB425-5141-4947-9B80-B5AE9DA1CA88
author name string	R D Goldin G C Farrell B R Bacon
rdfs:label	Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group (en) Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group (nl)
skos:prefLabel	Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group (en) Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group (nl)
name	Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group (en) Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group (nl)
title	wds:Q74428457-692DE4A1-ECAF-4618-8DFB-C6F41860BB33
title	Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study (en)
page(s)	wds:Q74428457-DCE99108-8F46-4016-A219-2CDE0A2A4BA5
page(s)	1121-1127
instance of	wds:Q74428457-E8B048D2-C622-4D55-9D83-A11EF41D4ED7
instance of	scholarly article
main subject	wds:Q74428457-0518B295-0CA4-4658-B001-4394A82D59E9 wds:Q74428457-53166316-6DA9-4304-8472-EB63447F98BC wds:Q74428457-81FB77A9-B18B-4BB6-9730-FD0CDF5805F0
main subject	hepatitis C chronic hepatitis chronic hepatitis C
PubMed ID	wds:Q74428457-B4406C97-5EFF-49EF-B7BA-941C4B5C7D03
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9537453
PubMed ID	9537453
published in	wds:Q74428457-D30D6480-341B-4FC2-929F-E9799AE2DA32
published in	Hepatology
issue	wds:Q74428457-39AD1933-E8AB-4030-A4F2-126A3F5A246B

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software